1.
N Engl J Med
; 386(11): 1005-1007, 2022 Mar 17.
Article
in English
| MEDLINE
| ID: mdl-35275477
2.
JAMA
; 327(3): 204-206, 2022 Jan 18.
Article
in English
| MEDLINE
| ID: mdl-34964806
Subject(s)
Respiratory Syncytial Virus Infections/prevention & control , Respiratory Syncytial Virus Vaccines , Respiratory Syncytial Virus, Human/immunology , Vaccine Development , Aged , Antibodies, Monoclonal/immunology , Antibodies, Neutralizing/immunology , Antibodies, Neutralizing/isolation & purification , Clinical Trials as Topic/history , History, 20th Century , History, 21st Century , Humans , Infant , Respiratory Syncytial Virus Infections/history , Respiratory Syncytial Virus Infections/mortality , Respiratory Syncytial Virus Vaccines/adverse effects , Respiratory Syncytial Virus Vaccines/history , United States/epidemiology , Vaccine Development/history , Viral Fusion Proteins/chemistry , Viral Fusion Proteins/immunology , Viral Proteins/chemistry , Viral Proteins/immunology , Viral Proteins/ultrastructure
3.
Immunity
; 54(12): 2676-2680, 2021 12 14.
Article
in English
| MEDLINE
| ID: mdl-34739870
ABSTRACT
The 2005 Immunity paper by Karikó et al. has been hailed as a cornerstone insight that directly led to the design and delivery of the mRNA vaccines against COVID-19. We asked experts in pathogen sensing, vaccine development, and public health to provide their perspective on the study and its implications.
